Endocrine Abstracts

Objectives: to evaluate the clinical and biochemical effects of (SGLT2) inhibitors as a fourth oral anti-diabetic drug in patients with type 2 diabetes mellitus (T2DM).

Patients (Materials) and Methods: In a tertiary hospital in Karachi, Pakistan, a retrospective assessment of patient medical records was conducted from January 1, 2017 to December 31, 2020.A total of 100 patients (mean age [Standard Deviation]: 53.8 [9.63] years) with poorly controlled T2DM were included. Data was collected before the SGLT-2 inhibitor was added, as well as three and six months after the medicine was started. Weight, Body Mass Index, blood pressure (BP), HbA1c, SGPT, and Creatinine were measured at the start and during the study

Results: There was a significant reduction in HbA1c (P-value < 0.001) with (Mean Reduction [Standard Deviation)) 0.81[1.02] % at 3 months and 1.07[1.11] % at 6 months, Weight (P-value < 0.001) with (MR [SD]) 1.83[2.32] kg at 3 and 4.02[6.04] kg at 6 months, BMI with 0.69[0.95] kgm-2 at 3 months and 2.13[3.41] kgm-2 at 6 months of follow up. Systolic Blood Pressure showed significant reduction (P-value < 0.05) of 5.9[15.76] mmHg at 3 months and 6.37[18.33] mmHg at 6 months. Mild variation in creatinine and SGPT was also noted.

Conclusions: SGLT-2 is a safe and effective oral anti-diabetic medicine that can help individuals with diabetes who are currently using glucose-lowering or anti-diabetic medications. These medications can be used as an alternative to injectable insulin for people who do not want to use it, and they can help diabetic patients stick to their regimen.

Keywords: SGLT2 Inhibitors, T2DM, Weight loss